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Although osteoarthritis (OA) aetiology is complex, genetic, genomic and epigenetic studies published
within the last decade have advanced our understanding of the molecular processes underlying this
common musculoskeletal disease. The purpose of this narrative review is to highlight the key research
articles within the OA genetics, genomics and epigenetics fields that were published between April 2018
and April 2019. The review focuses on the identification of new OA genetic risk loci, genomics techniques
that have been used for the first time in human cartilage and new publicly available databases, and
datasets that will aid OA functional studies.
Fifty-six new OA susceptibility loci were identified by two large scale genome wide association study
meta-analyses, increasing the number of genome-wide significant risk loci to 90. OA risk variants are
enriched near genes involved in skeletal development and morphology, and show genetic overlap with
height, hip shape, bone area and developmental dysplasia of the hip. Several functional studies of OA loci
were published, including a genome-wide analysis of genetic variation on cartilage gene expression. A
specialised data portal for exploring cross-species skeletal transcriptomic datasets has been developed,
and the first use of cartilage single cell RNAseq analysis reported. This year also saw the systematic
identification of all microRNAs, long non-coding RNAs and circular RNAs expressed in human OA
cartilage. Putative transcriptional regulatory regions have been mapped in human chondrocytes
genome-wide, providing a dataset that will facilitate the prioritisation and characterisation of OA genetic
and epigenetic loci.
© 2020 The Authors. Published by Elsevier Ltd on behalf of Osteoarthritis Research Society International.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).Introduction
Osteoarthritis (OA) is a chronic musculoskeletal disease char-
acterised by the destruction of articular cartilage, synovial inflam-
mation and bone remodelling. Although disease aetiology is
complex, our understanding of the molecular processes underlying
OA has been advanced through genetic, genomic and epigenetic
studies1e3. The goal of this annual review is to summarise the
progress made within this field between April 2018 and April 2019.
We have chosen to focus on the identification of new OA genetic
risk loci and on new genomics techniques that have been used in
human cartilage for the first time. We also highlight new publically
available datasets and databases that will aid future functional
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Identification of new OA genetic risk loci
Identification of genetic loci using hypothesis-free genomewide
association studies (GWAS) has given novel insights into dis-
eases4e6, identified potential drug targets7, and led to the use of
polygenic risk scores in selecting individuals for clinical trials8.
However, until recently, identification of OA loci was trailing behind
other complex diseases and phenotypes such as rheumatoid
arthritis (over 100 risk loci;9) and height (over 3,000 loci;10), with
only 19 OA loci reported up to April 2017 at genome wide signifi-
cance level of P  5  108 (Fig. 1(A), Table I,11e21). The number of
significant OA genetic risk loci has now increased to 90
(Table I,22e29), the majority of which have small effects sizes (odds
ratios [OR] 1.03 to 1.25, Fig. 1(B)). As the number of samples
included in the analysis has a significant effect on the number of
loci identified30, the increase in loci is largely explained by the
publication of several large scale, well powered OA GWAS. Four of
these studies have utilised genotyping and medical data forsearch Society International. This is an open access article under the CC BY license
Fig. 1
OA genetic risk loci. A) Number of OA genetic risk loci identified at the genome-wide significance level by
date. The number of loci has increased from 19 to 90 since the release of the UK biobank (UKBB) geno-
typing data, which was used in four OA GWAS studies published in 2018 and 201926e29. A full list of
genome-wide significant OA loci is available in Table I. B) Odds ratio (OR) of OA risk alleles plotted against
allele frequency for all OA SNPs listed in Table I. Arrows point towards the variants with the highest OR and
highest OA risk allele frequency, with the nearest gene to these two variants indicated. Note, for some loci
several SNPs have been reported. C) Overlap in the new OA risk loci identified in the deCODE-UKBB and
arcOGEN-UKBB studies29,30. The name of the nearest gene to the associated DNA variant is given; this
may not be target gene of the OA. The variant identifier for each OA signal is given in Table I. *The OA
variant is also associated with height at P < 5  10828. The number of OA cases and controls for each
analysis is shown in brackets. # Two independent signals were reported overlapping theMAPT gene in the
arcoGEN-UKBB study. Two independent COL11A1 signals were identified in the deCODE-UKBB study,
one of which was also identified in the arcOGEN-UKBB study and was associated with height in28.
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https://www.ukbiobank.ac.uk/), together with existing OA GWAS
cohorts26e29. The two largest OA analyses were published within
the last year and together they identified 56 new loci (Fig. 1(B) and
(C);28,29). Unlike the majority of previous OA studies, which have
employed the traditional GWAS design of signal discovery followed
by replication, both studies performed a meta-analysis of the UKBB
data together with the Icelandic deCODE genetics28 or UK arcOGEN
datasets29. This meta-analysis approach has several advantages,including increasing the power to detect genetic variants with
small tomodest effects sizes whist reducing the probability of false-
negative results and identify effect size heterogeneity across
cohorts31.
The deCODE-UKBB study included over 650,000 British and
Icelandic individuals, making it the biggest OA GWAS published to
date28. They analysed 11.6 million genotyped variants present in
both cohorts, performing separate meta-analyses for hip and knee
OA [Fig. 1(C)]. The same OA definition was used for both cohorts,
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injury and acetabular dysplasia) were excluded, yielding a total of
17,151 OA hip cases, 23,877 OA knee cases and up to 619,289 con-
trols (individuals without any medical record of OA). They identi-
fied 23 independent associations at 22 loci in the additive meta-
analyses (odds ratios [OR] 1.06 to 2.84) and two loci using a
recessive mode (OR 1.95e5.89). This included 12 novel hip loci, four
novel knee loci and replication of numerous existing loci including
CHADL, GDF5 and FILIP1. The arcOGEN-UKBB study analysed up to
17.5 million variants in over 455,000 UK individuals, reporting 65
genome-wide significant variants mapping to 64 loci29. Separate
analyses were performed for four OA phenotypes; OA hip, OA knee,
hip and/or knee OA and OA at any site, although different OA def-
initions were used in the two cohorts. Fifty-two novel loci with ORs
of 1.03e1.83 were reported, comprising of 15 new hip loci, seven
knee loci, six hip and/or knee loci and 24 loci for OA at any site. Of
the novel loci reported by these two meta-analyses, twelve were
significant at the genome-wide level in both studies, including
variants mapping to the LMX1B, COL11A1 and IL11 genes (Table I,
Fig. 1(C)); a larger overlap is observed when considering all signals
that reach genome-wide suggestive P values These studies
confirmed that there are joint-site differences in genetic risk, with
the majority of loci only associated with OA at a specific joint
(Table I). For example, the two signals with the most significant P
values in both studies, mapping to the GDF5 and PTHLH loci, were
only significant for knee or hip OA respectively.
Pathway analysis revealed that OA loci are enriched near genes
involved in skeletal development and/or associated with rare
monogenic bone diseases29. This includes the TGFb pathway genes
TGFB1, LTBP1, LTBP3 and SMAD3, and the recently identified ROCR
long non-coding RNA (lncRNA) that acts upstream of SOX9 during
chondrogenic differentiation32. New OA pathways may be identi-
fied in the near future with the publication of the first multi–ethnic
OA GWAS meta-analysis study performed by the Genetics of
Osteoarthritis consortium (33; https://www.genetics-osteoarthritis.
com/home/index.html). This is a global collaboration of 18 GWAS
cohorts from Europe, Japan, Hong Kong and the USA, and includes
more than twice the number of OA cases used in previous GWAS
studies. In addition to hip and knee OA, meta-analyses are also
being performed for spine, thumb and finger OA33.Genetic overlap of OA with hip morphology, height, bone area and
DDH
It has been hypothesised that OA genetic risk loci may act during
skeletal development, causing subtle differences in joint develop-
ment and shape that, through alterations of joint biomechanics,
predispose the individual to OA later in life3,34,35. Several genetic
studies published this year have provided further evidence of this
hypothesis, with DNA variants associated with height28, hip
shape36, and developmental dysplasia of the hip (DDH;37) over-
lapping OA loci. The genetic link between OA risk and height was
examined in the deCODE-UKBB GWAS, with 12/25 OA loci associ-
ated with increased (e.g., FAM101A, FILIP1) or decreased height (e.g.,
COL11A1, GDF5) at the genome-wide significance level (Table I,
Supplemental Table 1;28). The first GWAS for hip shape used DXA
scans of almost 16,000 individuals from five cohorts, and identified
nine loci at P < 5  109 and 12 at P < 5  10836. Two signals
overlapped the established OA hip loci near the PTHLH and ASTN2,
and another signal was located downstream of ROCR, overlapping
the ROCR/SOX9 OA knee loci reported in the arcoGEN-UKBB
GWAS29. Co-localisation analysis suggested a shared causal variant
for hip shape, OA and height at the ASTN2 locus, and for OA and hip
shape at the PTHLH locus.DDH is the most common developmental musculoskeletal dis-
ease and is characterised by abnormal development of the hip joint,
a risk factor for degenerative hip diseases including OA. The largest
DDH GWAS to date identified an association between the GDF5 OA
knee SNP rs143384 and DDH in European individuals37, confirming
previous reports of a suggestive association in Asian populations38.
rs143384 explained approximately 1% of DHH heritability, with fine
mapping indicating this SNP had >99% likihood of being the causal
DDH variant at the locus. rs143384 is also associated with hip
intertrochanteric/shaft and trochanter bone area as well as bone
area of the lumbar spine39. Although GDF5 is not a risk locus for hip
OA in Europeans28,29, a new study in mice demonstrated a direct
link between this gene and hip morphology40. Compared to het-
erozygous mice, mice lacking the GDF5 gene had abnormal prox-
imal femur and acetabular morphology, including smaller femoral
heads and neck. These dysmorphologies are concordant with
changes that cause hip instability, injury and adult onset OA in
humans.
Functional studies of OA loci
Once a DNA region harbouring OA genetic risk has been iden-
tified by GWAS, functional studies are required to pinpoint the
causal variant(s), target gene(s), cell or tissue type inwhich this risk
allele is acting, and when in the lifecourse this occurs. Although
such functional studies have lagged behind identification of risk
loci for many diseases41, there have been several functional studies
of individual OA loci published this year. Together, these studies
have prioritised candidate genes42, highlighted potential mecha-
nisms of action42e44, and examined the role of target genes in
cartilage homeostasis and disease using mouse models45,46. How-
ever, with identification of 56 new loci in the last year, there is a
need to prioritise specific DNA variants and genes from within risk
loci for functional studies in a rapid and systematic way.
The majority of common disease causing SNPs, including those
for OA, are thought to act by altering transcription factor binding,
subtly affecting transcription of nearby genes such that one allele
drives higher gene expression than the other, termed allelic
imbalance (AI). Online tools such as HaploReg47 and LDlink48 are
invaluable for prioritising potential target genes and highlighting
putative causal variants within a locus, some of which contain
100se1000s of variants in high linkage disequilibrium (LD) with
the OA SNP (see Table I). These tools integrate genetic data from the
1,000 Genomes Project49 with chromatin status, transcription fac-
tor binding, and DNaseI hypersensitivity (DHS) mapping generated
by the ENCODE50 and Epigenome Roadmaps projects51, and gene
expression data from the GTEx Project (https://gtexportal.org/
home/). Although chromatin state information is available for iso-
lated osteoblasts and in vitro differentiated chondrocytes, there are
limitations in the application of these tools for OA studies as the
majority of data used for variant and gene prioritisation has been
generated in non-synovial joint tissues.
However, a study published this year sought to detect all tran-
script SNPs showing AI in OA cartilage52, creating an important
dataset for OA functional studies. RNAseq data was combined with
genotype data for 42 OA cartilage samples in order to provide a
downloadable dataset for probing the effect of genetic variants on
gene expression in this disease relevant tissue (available at http://
onlinelibrary.wiley.com/doi/10.1002/art.40748/abstract). A total
2070 SNPs marking AI in 1,031 cartilage expressed genes were
identified, including SNPs within the known OA risk loci ALDH1A2,
MGP and COL11A1. Integration of the dataset with DNA variants in
high linkage disequilibrium (LD, r2  0.8) with the new OA signals
reveals AI of OA SNPs within the novel COL11A1, LTBP1, TNC, and
SLC44A2 loci (Table I). Moveover, a DNA variant at the SBNO1 locus
chr variant ID trait Ref EA/NEA EAF OR locus ID nearest gene SNPsz others traits AI ATAC seq SNPs
chr 1 rs3753841* hip 28 A/G 0.610 1.08 COL11A1 COL11A1 22 He, BA [ COL11A1 2
rs2126643* hip 28 C/T 0.655 1.10 COL11A1 1 He
rs4338381y hip 29 A/G 0.630 1.10 COL11A1 15 1
1:150214028z,y OA 29 del/T 0.370 1.03 ANP32E ANP32E 1
rs550034492z,y OA 29 TA17/Tdel 0.570 1.03 RABGAP1L RABGAP1L 1
rs11583641y hip 29 C/T 0.720 1.08 COLGALT2 COLGALT2 7
rs2820436 OA 27 A/C 0.318 1.08 LYPLAL1-AS1 LYPLAL1-AS1 49
rs2785988* hip 28 A/C 0.317 1.08 LYPLAL1-AS1 22
rs2820443 H&/K 29 C/T 0.300 1.06 LYPLAL1-AS1 21
rs10218792y OA 29 G/T 0.270 1.04 KIF26B KIF26B 3
chr 2 rs2061026* knee 28 A/G 0.488 1.06 LTBP1 LTBP1 119 He Y LTBP1 5
rs2061027y OA 29 A/G 0.510 1.04 LTBP1 125 Y LTBP1 5
rs3771501 OA 27 A/G 0.448 1.06 TGFA TGFA 26 4
rs3771501 OA 29 A/G 0.470 1.05 TGFA
rs12470967z,y knee 29 A/G 0.430 1.06 SDPR SDPR 1
rs62182810y OA 29 A/G 0.550 1.03 RAPH1 RAPH1 46 1
chr 3 rs7639618 knee 12 G/A 0.630 1.43 COL6A4P1 COL6A4P1 80
rs62262139z,y OA 29 A/G 0.540 1.04 RBM6 RBM6 123 7
rs6976 TJR 18 T/C 0.401 1.12 GNL3/ITIH GNL3 326 10
rs678 hip 28 T/A 0.368 1.08 ITIH1 304 He 11
rs3774355 hip 29 A/G 0.360 1.09 ITIH5 305 11
rs12107036 TKR(F) 18 G/A 0.497 1.21 TP63 TP63 1
chr 4 rs11732213y H&/K 29 T/C 0.810 1.06 FAM53 FAM53 70 10
rs1913707y hip 29 A/G 0.610 1.08 RAB28 RAB28 5
rs34811474y OA 29 G/A 0.770 1.04 ANAPC4 ANAPC4 1
rs11335718 OA 27 del/C 0.112 1.11 ANXA3 ANXA3 2
rs13107325y OA 29 T/C 0.080 1.10 SLC39A8 SLC39A8 3
chr 5 rs35611929y knee 29 A/G 0.340 1.06 AP3B1 AP3B1 6
rs3884606y H&/K 29 G/A 0.490 1.04 FGFR18 FGFR18 5 1
chr 6 rs1800562* hip-rec 28 G/A 0.073 1.95 HFE/HIST1H2BC HFE 8 2
rs115740542y OA 29 C/T 0.070 1.06 HIST1H2BC 6 2
rs10947262 knee 13 C/T 0.580 1.31 BTNL2 BTNL2 14
rs7775228 knee 13 T/C 0.620 1.34 HLA locus HLA locus 4
rs9277552y H&/K 29 C/T 0.790 1.06 HLA-DPA1 HLA-DPA1 17
rs12154055y OA 29 G/A 0.610 1.03 CDC5L CDC5L 1
rs10948172 male 18 G/A 0.285 1.14 SUPT3H/RUNX2 SUPT3H 240 5
rs2396502 hip 29 C/A 0.600 1.09 RUNX2 108 1
rs1997995 hip 28 G/A 0.339 1.09 RUNX2 9
rs80287694y hip 29 G/A 0.110 1.12 BMP5 BMP5 6
rs12209223 hip 28 A/C 0.107 1.16 FILIP1 FILIP1 7 He 1
rs12209223 hip 29 A/C 0.100 1.17 FILIP1 7 1
rs9350591 hip 18 T/C 0.126 1.18 FILIP1 91 2
rs11409738z,y OA 29 TA/T 0.370 1.04 DYNC1L1 DYNC1L1 8
chr 7 rs11764536* hip 28 C/A 0.023 1.26 HDAC9 HDAC9 2
rs3815148 K&/Hd 14 C/A 0.230 1.14 DUS4L/COG5 COG5 328 7
rs4730250 knee 15 G/A 0.170 1.17 DUS4L 73
rs143083812* hip 28 T/C 0.001 2.84 SMO SMO 1 1
rs7792864 knee 24 C/G 0.880 2.35 linc01006 linc01006 2
chr 8 rs330050y OA 29 G/C 0.510 1.04 PPP1R3B PPP1R3B 26 5
rs4733724* hip 28 A/G 0.790 1.11 GSDMC GSDMC 89 He 10
rs60890741z,y hip 29 C/CA 0.860 1.11 GSDMC 10 2
rs11780978 hip 27 A/G 0.387 1.13 PLEC PLEC 108 Y PLEC 24
chr 9 rs116882138 H&/K 27 A/G 0.014 1.25 MOB3B MOB3B 1
rs10116772 H&/K 26 C/A 0.600 1.03 GLIS3 GLIS3 8 1
rs10974438 OA 29 A/C 0.650 1.03 GLIS3 2
rs1078301* knee 28 T/A 0.269 1.07 COL27A1 COL27A1 7 3
rs919642y OA 29 T/A 0.270 1.05 COL27A1 7 3
rs2480930* hip 28 A/G 0.494 1.09 TNC TNC 29 Y TNC 4
rs1330349y hip 29 C/G 0.580 1.08 TNC 16 2
rs4836732 THR(F) 18 C/T 0.450 1.20 ASTN2 ASTN2 2
rs13283416 hip 28 G/T 0.424 1.10 ASTN2 3 He, HS
rs34687269 hip 29 A/T 0.530 1.09 ASTN2 8
rs10760442* hip 28 G/A 0.621 1.09 LMX1B LMX1B 10 1
rs62578127y hip 29 C/T 0.630 1.09 LMX1B 10 1
chr 11 rs17659798y H&/K 29 A/C 0.710 1.06 mir8068 mir8068 2
rs11031191y OA 29 T/G 0.350 1.03 DCDC5 DCDC5 9
rs10896015* hip 28 G/A 0.738 1.09 LTBP3 LTBP3 15 5
rs10896015y hip 29 G/A 0.730 1.08 LTBP3
rs34419890y hip 29 T/C 0.930 1.13 C11orf80 C11orf80 9
rs1149620y OA 29 T/A 0.570 1.04 TSKU TSKU 6
chr 12 rs4764133 hand 25 T/C 0.390 x MGP/ERP27 ERP27 145 Y MGP 13
(continued)
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rs10843013 hip 28 C/A 0.211 1.14 PTHLH/KLHL42 KLHL42 5
rs10492367 hip 18 T/G 0.183 1.14 KLHL42 5 HS
rs10492367 hip 29 T/G 0.190 1.16 KLHL42
rs79056043y hip 29 G/A 0.050 1.18 LRIG3 LRIG3 17 4
rs317630y OA 29 T/C 0.270 1.04 CPSF6 CPSF6 40
rs11105466y H&/K 29 A/G 0.420 1.04 linc02399 linc02399 27 1
rs2171126y OA 29 T/C 0.510 1.03 CRADD CRADD 41 2
rs835487 THR 18 G/A 0.340 1.13 CHST11 CHST11 8 1
rs11059094y hip 29 T/C 0.480 1.08 BCL7A/MLXIP MLXIP 164 2
rs1060105* knee 28 C/T 0.774 1.07 SBNO1 SBNO1 226 He [ CDK2AP1 5
rs56116847y knee 29 A/G 0.360 1.06 SBNO1 11
rs4765540* hip 28 C/T 0.253 1.08 FAM101A FAM101A 2 He
chr 13 rs11842874 H&/K 17 A/G 0.919 1.17 MCF2L MCF2L 11 3
chr 15 rs35912128z,y knee 29 AT/A 0.170 1.08 USP8 USP8 109 2
rs3204689 hand 20 C/G 0.525 1.46 ALDH1A2 ALDH1A2 56 Y ALDH1A2 5
rs4775006 knee 29 A/C 0.410 1.06 ALDH1A2 10 [ ALDH1A2 2
rs12901071 H&/K 23 A/G 0.080 1.08 SMAD3 SMAD3 2
rs12901372 hip 28 C/G 0.553 1.08 SMAD3 23 4
rs12901372 hip 29 C/G 0.530 1.08 SMAD3
rs35206230y OA 29 T/C 0.670 1.04 CSK CSK 25 4
chr 16 rs8044769 female 18 C/T 0.537 1.11 FTO FTO 9 1
rs9930333 H&/K 29 G/T 0.420 1.05 FTO 89 5
rs6499244y knee 29 A/T 0.560 1.06 NFAT5/WWP2 NFAT5 85 9
rs34195470* knee 28 G/A 0.538 1.07 WWP2 3 He
rs864839 hip 27 T/G 0.691 1.08 JPH3 JPH3 3
rs1126464y OA 29 G/C 0.760 1.04 DPEP1 DPEP1 2 1
chr 17 rs35087650z,y knee 29 TT/del 0.260 1.07 SMG6 SMG6 1
rs2953013y H&/K 29 C/A 0.300 1.05 NF1 NF1 240 3
rs62063281y hip 29 G/A 0.220 1.10 MAPT MAPT 3,136
rs547116051z,y OA 29 AC/A 0.001 1.83 MAPT 1
rs7222178* hip 28 A/T 0.205 1.09 NACA2 NACA2 3
rs7222178y hip 29 A/T 0.200 1.10 NACA2
rs2521349 hip 27 A/G 0.410 1.13 MAP2K6 MAP2K6 25 [ MAP2K6 2
rs8067763y knee 29 G/A 0.410 1.06 SOX9/ROCR ROCR 9 He
chr 18 rs10502437y OA 29 G/A 0.600 1.03 TMEM241 TMEM241 7
chr 19 rs1560707y OA 29 T/G 0.370 1.04 SLC44A2 SLC44A2 62 Y SLC44A2 7
rs12982744 male 19 C/G 0.618 1.17 DOT1L DOT1L 25
rs375575359 knee 27 del/T 0.040 1.21 ZNF345 ZNF345 1
rs75621460y OA 29 A/G 0.030 1.16 TGFB1 TGFB1 1 1
rs4252548* hip 28 T/C 0.021 1.30 IL11 IL11 1 He
rs4252548y hip 29 T/C 0.020 1.32 IL11
chr19:18898330 THR 22 G/C 0.003 16.7 COMP COMP 1
chr 20 rs143383 hip 11 T/C 0.740 1.79 GDF5 GDF5 108
rs143383 knee 16 T/C 0.609 1.17 GDF5 113 10
rs143384 knee 28 A/G 0.614 1.10 GDF5 5 He, DDH, BA 3
rs143384 knee 29 A/G 0.600 1.10 GDF5
rs6094710 hip 21 A/G 0.040 1.28 NCOA3 NCOA3 13
chr 21 rs6516886 hip 27 T/A 0.764 1.10 RWDD2B RWDD2B 32 1
rs2836618y hip 29 A/G 0.260 1.09 ERG ERG 29 3
rs532464664 hip-rec 22 ins8/- 0.039 7.70 CHADL CHADL 1
chr 22 rs117018441 hip-rec 28 T/G 0.032 5.89 CHADL 1
rs528981060z,y OA 29 A/G 0.001 1.68 SCUBE1 SCUBE1 1
The number of variants with an r2  0.8 (referred to the LD class in28) of the OA variant calculated by LDlink48 using the 1,000 Genomes Project phase three data49 in the
same population(s) as the GWAS study; other traits: loci also significantly associated with height (He,28), bone area (BA,39), hip shape (HS,36) and developmental dysplasia
of the hip (DDH,37); AI: overlap of all DNA variants within the LD class and transcript SNPs from 52 showing significant allelic imbalance (AI) in cartilage. The effect of the OA
risk allele on gene expression is shown ([ ¼ increased and Y ¼ decreased); ATACseq SNPs: number of DNA variants within the LD class that overlap ATACseq peaks in
cartilage identified in77. The ATACseq peaks in hg38 were lifted over into hg19 using the UCSC LiftOver tool and overlapped with OA DNA variants using the UCSC Data
Integrator tool. An extended version of this table is available as Supplemental Table 1.
* novel loci identified in the deCODE-UKBB study28.
y Novel loci identified in the arcOGEN-UKBB study30.
z Loci only analysed in the UKBB cohort in29;H&/K: hip and/or knee OA; TJR: total joint replacement; TKR(F): total knee replacement (female); hip-rec: recessive hip OA;
K&/Hd: knee and/or hand OA; THR(F): total hip replacement (female); EA: effect (OA risk) allele; NEA: non-effect allele; OR: odds ratio.
Table I
OA genetic risk loci identified at the genome-wide significance level.Note, the nearest gene refers
to the nearest gene in 2D to the GWAS variant, which may not be the gene the genetic loci is acting
upon to increase OA susceptibility
Osteoarthritis
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CDK2AP1 gene rather than SBNO1 itself, highlighting the usefulness
of this dataset for prioritising genes as well as variants within OA
susceptibility regions.
Transcriptomics
A wealth of novel human skeletal transcriptomic analyses were
published the last year, including RNAseq based datasets of OA
cartilage52e55, timecourse analysis of in vitro chondrogenesis56,57
and profiling of human foetal chondrocytes, myoblasts, osteoblasts,
ligamentocytes and tenocytes57. Such RNAseq datasets generate a
huge treasure trove of gene expression information, although the
published studies typically focus only on a small subset of the data,
with the remaining data either relegated to supplemental files or
not provided. Furthermore, it is difficult to compare the results
between studies due to differences in data analysis methods. These
issues have been addressed by SkeletalVis, a new online web
application designed as a specialised meta-analysis portal for
skeletal disease transcriptomic datasets (http://phenome.
manchester.ac.uk/ 58). The portal currently contains microarray
and RNAseq data from 300 studies encompassing a total of 779
individual analyses in cartilage and other OA-relevant tissues.
SkeletalVis permits exploration and comparison of existing human
and animal model datasets, including the identification of gene
signatures across studies and species. Furthermore, the user can
upload their own unpublished data in order to compare it to
existing datasets and perform downstream analyses, including
transcription factor and gene ontology enrichment analysis. The
portal also allows the expression of a specific gene to be compared
across the different experiments, a very useful tool for preliminary
analysis of OA-associated genes identified through GWAS, tran-
scriptomic and epigenomic studies.
Although bulk RNAseq studies are now the norm, advances in
sequencing technology have allowed the transcriptome to be ana-
lysed at the level of individual cells. Single cell RNA sequencing
(scRNAseq) is becoming increasingly popular, leading to new in-
sights into development and disease59. This year, the first human
cartilage single-cell RNAseq analysed the transcriptome of 1,464
chondrocytes isolated from the tibial plateau of 10 knee patients60.
Seven molecular subgroups of OA chondrocyte were identified,
including three novel populations termed effector (EC), regulatory
(RegC) and homeostatic (HomC) chondrocytes. These subgroups
can be classified based on expression of 792 genes, several of which
map to newly identified OA susceptibility regions (e.g., GLIS3,
TGFB1, TNC andWWP2). Single cell analysis of OA synovium has also
been performed, with Chou and colleagues reporting analysis of
over 10,000 synovial cells and 26,000 OA chondrocytes from three
OA knee patients at OARSI 201961. The number of single-cell RNA-
seq analyses of OA-relevant tissues is expected to rise over the next
few years and these studies have the potential to identify new
pathological cell types and pathways.
Epigenetics
MicroRNAs
Numerous microRNAs (miRNAs) have now been associated with
cartilage development or homeostasis and during the development
of OA62. To identify candidate miRNAs for future miRNA-based OA
therapies, a study this year aimed to identify all cartilage miRNAs
involved in OA pathophysiology53. They leveraged mRNA and small
RNA-seq data from 19 paired damaged and intact OA knee and hip
cartilage samples in order to create a chondrocyte-specific inter-
action network of miRNAs with their target mRNAs. Utilisingpredicted and validated miRNA target databases, an ‘OA-specific
miRNA interactome’ of 62 differentially expressed miRNAs and 238
differentially expressed target mRNAs was generated. One notable
miRNA was miR-99a-3p, which had not been associated with OA
prior to the study. miR-99a-3p was downregulated in lesioned OA
cartilage and targeted 36 genes, including FZD1, ITGB5 and GDF6. A
second large miRNAemiRNA cluster centred on the upregulated
miRNA miR-143e3p, and consisted of 16 target genes including
DCAKD, AMIGO1 and SMAD3. Importantly, functional validationwas
performed for both miR-99a-3p and miR-143e3p, confirming
several of the identified target interactions.
A number of other studies published this year have further
expounded targets of miRNAs in cartilage and bone with implica-
tions for skeletal development and homeostasis. One study focused
on miR-20463, which is upregulated in human damaged OA carti-
lage and mouse cartilage with age or after OA induction. miR-204 is
also induced by number of senescence inducers (including H202
and infra-red radiation). Interestingly miR-204 repressed chon-
drocyte sulphated glycosaminoglycan production by directly tar-
geting a number of transcripts involved in cartilage proteoglycan
biosynthesis, including genes crucial for chondroitin sulphate (CS)
and hyaluronic acid formation. Furthermore, in vivo intra-articular
injections of a miR-204 mimic exacerbated cartilage damage in the
mouse DMM model, while miR-204 inhibitor injection caused a
reciprocal protection against experimental OA. Inhibition of miR-
204 in human chondrocytes could similarly upregulate CS levels
and suppress catabolic MMP expression.
A second study focused on miR-181a-5p, which is increased in
degenerated human facet joints and OA knee cartilage, and during
mouse OA development64. Injection of antisense oligonucleotides,
which attenuate miR-181a-5p activity, reduced cartilage damage in
knee joints with concomitant reduction in catabolic gene expres-
sion and markers of cartilage damage. This finding was confirmed
in human cartilage explants and further work is required to char-
acterise the targets and pathways mediating the effect of miR-
181e5p in chondrocytes.
The crucial role of miR-140 in skeletal development is well
established65,66, and a novel pathological mutation within this
miRNA was recently described67. An A > G nucleotide substitution
within the miR-140e5p seed region caused a novel human skeletal
dysplasia with features including short stature, brachydactyly and
delayed epiphyseal ossification leading to degenerative joint dis-
ease. This mutation causes both de-repression of conserved miR-
140e5p targets and suppression of an additional repertoire of
genes that are targeted by the new seed sequence. These include
genes required for skeletal development such as Loxl3 and Hif1a.
Importantly, a knock-in mouse model containing the human miR-
140e5p seed mutation had skull, cartilage and long bone devel-
opment alterations, phenocopying the skeletal dysplasia features of
the patients.
Other key findings in the miRNA field include the observation
that miR-138-mediated inhibition of osteogenesis could be rescued
by overexpression of its target RhoC68, miR-93e5p may target TCF4
to prevent cartilage matrix degradation69, and finally, that miR-
324e5p is upregulated in OA and targets the hedgehog signalling
pathway in chondrocytes70.
Other non-coding RNAs
Unlike miRNAs, research into the role of other types of non-
coding RNAs in OA and cartilage remains in its infancy. These
include long noncoding RNAs (lncRNAs), a diverse group of non-
coding transcripts over 200 nt in length. Although the role of in-
dividual lncRNAs such as ROCR32 have been investigated (reviewed
in71), the first study to characterise lncRNAs genome-wide in OA
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to define the lncRNA transcriptome in OA cartilage by analysing
both hip and knee cartilage RNA-seq data and identified a total of
1834 lncRNAs. Twenty lncRNAs were significantly differentially
expressed between both OA and non-OA hip cartilage and pre-
served and damaged regions of OA knee cartilage, including the
imprinted gene MEG3. Future work will focus on the identification
of lncRNA functions in cartilage, thereby enabling investigation into
the consequence of lncRNA expression changes in OA.
Circular RNAs (circRNAs) are single-stranded RNAs usually
formed by alternative splicing of pre-mRNAs in which the 50 and 30
ends have been spliced together to form a loop72. Systematic
analysis of circRNAs expressed in OA cartilage identified CircSER-
PINE2, which is formed by circularisation of exons 2e4 of the serine
protease inhibitor gene SERPINE273. The expression of CircSER-
PINE2 in human cartilage was comprehensively validated and
found to be downregulated in OA in contrast to the linear SERPINE2
transcript. This circRNA is downregulated during OA and intra-
articular overexpression of CircSERPINE2 alleviated OA severity in a
rabbit model. Specific inhibition of CircSERPINE2 by siRNA caused
the suppression of key cartilage genes such as SOX9 and the upre-
gulation of catabolic genes such asMMP13. CircSERPINE2 pulldown
experiments identified binding of miR-1271, which is upregulated
in OA, and the authors posited that CircSERPINE2 acts as a sponge
for miR-127e5p. Indeed overexpression of miR-1271 in chon-
drocytes phenocopied the effect of CircSERPINE2 siRNA, while in-
hibition of miR-1271 could rescue the phenotype. However, miR-
1271 is relatively lowly expressed in chondrocytes and other
studies have failed to detect expression changes in OA suggesting
other mechanisms of CircSERPINE2 action may still be
discovered74,75.
Genome-wide mapping of open chromatin and histone
modifications
Within the OA epigenetics field, the majority of research has
centred on DNAmethylation and non-coding RNAs. The few studies
of histone modifications have primarily focussed on the role of
individual chromatin remodelling proteins in cartilage (e.g.,
DOT1L;45,76) rather than genome-wide mapping of specific histone
modifications and open chromatin. Techniques used for the latter
analyses, namely chromatin immunoprecipitation sequencing
(ChIPseq) and DHS mapping, have previously required unfeasibly
large number of freshly isolated cells (typically 1  106 to
2  107 cells), preventing such studies in cartilage. However, this
has changed within the last year with publication of the first re-
ports of histone ChIPseq andmapping of open chromatin regions in
human chondrocytes57,77.
In the first study, Ferguson and colleagues performed ChIPseq of
fetal and adult chondrocytes for the active histone modifications
H3K4me1, H3K4me3 and H3K27ac, and the repressive H3K27me3
mark using only 10,000 chondrocytes per ChIP57. ChIPseq was also
generated from pluripotent stem cells at day 14 and day 60 of in
vitro chondrogenic differentiation. Matched RNAseq data available
for both in vitro differentiation timepoints as well as the fetal and
adult chondrocyte subtypes. Based on the combination of different
histone modifications, 12 chromatin states were identified,
including putative active promoter enhancer regions. Given the
utility of the chromatin state information for future epigenetic
studies, the authors have made the ChIPseq and RNAseq data
available to download (GSE111850 and GSE106292 respectively).
In the second study77, the open chromatin regions of preserved
and damaged regions of knee cartilage from eight OA patients were
mapped using the assay for transposase-accessible chromatin using
sequencing (ATACseq;78). This is a fast and sensitive alternativemethod to DHS mapping that requires 5,000 to 50,000 cells, mak-
ing analysis of cartilage and other primary joint tissues feasible. Of
the 109,215 accessible chromatin regions identified in this study
(available at https://www.nature.com/articles/s41598-018-33779-
z#MOESM1), 71.1% mapped to putative enhancer regions, and 4%
had altered accessibility between damaged and undamaged OA
chondrocytes. DNA variants within several established OA loci map
to these ATACseq peaks, as do the variants within 28 of the 56 new
OA loci, including LTBP1, LTBP3 and SBNO1 (Table I).Collectively,
these chromatin datasets will be an invaluable resource for iden-
tifying non-coding regulatory regions in cartilage, and will aid
prioritisation of OA risk variants and epigenetic changes for func-
tional analyses.
Summary
Within the last year, the number of OA genetic risk loci has
increased from 34 to 9028,29, with several OA loci also associated
with height, hip shape, DDH and bone area28,36,37,39. However,
functional studies are required to elucidate the molecular mecha-
nism whereby these variants increase OA risk. Integrating genetic
variants with genome-wide datasets of cartilage AI52, chromatin
states57 and open chromatin regions77 will inform functional ana-
lyses of these loci. RNA sequencing studies have characterised new
chondrocyte subtypes60 and systematically identified all miRNAs53,
lncRNAs54 and circRNAs73 present in OA cartilage. The number of
transcriptomic and epigenomic studies will continue to increase as
sequencing costs fall and technical difficulties are overcome. As
well as analysing cartilage from different joints at numerous time
points in development, adulthood and during OA disease progres-
sion, future studies will hopefully examine additional disease-
relevant tissues such as bone, synovium and fat pad.
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